MindMed’s LSD Anxiety Drug: Revisiting, Rethinking, But Maintaining My ‘Hold’ CallBy mariocazombo76@gmail.com / January 29, 2025
Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider January 28, 2025 / Edmund Ingham, LLY, LLY:CA, PFE, PFE:CA / By mariocazombo76@gmail.com
EyePoint: A Risky ‘Buy’ Ahead Of Key Readout For Long-Acting Eylea Rival January 30, 2025 / Edmund Ingham, EYPT / By mariocazombo76@gmail.com